VEGFA Polyclonal Antibody

$Paraformaldehyde-fixed, paraffin embedded Rat liver; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with VEGFA Polyclonal Antibody, Unconjugated (bs-20393R) at 1:400 overnight at 4\u00b0C, DAB staining.$

Paraformaldehyde-fixed, paraffin embedded Rat liver; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with VEGFA Polyclonal Antibody, Unconjugated (bs-20393R) at 1:400 overnight at 4\u00b0C, DAB staining.

$Paraformaldehyde-fixed, paraffin embedded Rat brain; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with VEGFA Polyclonal Antibody, Unconjugated (bs-20393R) at 1:400 overnight at 4\u00b0C, DAB staining.$

Paraformaldehyde-fixed, paraffin embedded Rat brain; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with VEGFA Polyclonal Antibody, Unconjugated (bs-20393R) at 1:400 overnight at 4\u00b0C, DAB staining.

Lane 1: Rat Cerebellum lysates; Lane 2: Rat Kidney lysates; Lane 3: Rat Cerebrum lysates; Lane 4: Rat Liver lysates probed with VEGFA Polyclonal Antibody, Unconjugated (bs-20393R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

$Lane 1: Human K562 cell lysates; Lane 2: Human MDA-MB-231 cell lysates probed with VEGFA Polyclonal Antibody, Unconjugated (bs-20393R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.$

Lane 1: Human K562 cell lysates; Lane 2: Human MDA-MB-231 cell lysates probed with VEGFA Polyclonal Antibody, Unconjugated (bs-20393R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

Applications

WB
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)
ICC

Reactivity

Predicted Reactivity

Human
Dog

Overview
Catalog #	bs-20393R
Product Name	VEGFA Polyclonal Antibody
Applications	WB, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC
Reactivity	Rat
Predicted Reactivity	Human, Dog
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human VEGFA
Immunogen Range	101-200/232
Clonality	Polyclonal
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	7422
Swiss Prot	P15692
Subcellular location	Secreted
Synonyms	Vascuoar endothelial growth factor A; VEGF A; vascular endothelial growth factor A isoform 2 precursor; Vegf; VEGFA; MGC70609; MVCD1; VEGF; VPF; VEGFA_HUMAN; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF; VEGF A Precursor.
Background	This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms.
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IHC-F	1:100-500
IF(IHC-P)	1:50-200
IF(IHC-F)	1:50-200
IF(ICC)	1:50-200
ICC	1:100-500

Applications

Reactivity

Predicted Reactivity

Search our catalog of hundreds of thousands of products